Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 18/20 | 0.57 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939045 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL3925341 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL3928902 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL7502609 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL3937496 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL3928509 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL3938094 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL3930073 | 0.92 | TLR4 (0.69) | TLR4 | |
| SCHEMBL2000801 | 0.83 | TLR4 (0.57) | TLR4TLR2 | |
| SCHEMBL3939137 | 0.83 | TLR4 (0.72) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6764840-B2 | AUGMENT ANTIBODY PRODUCTION IN IMMUNIZED ANIMALS AS WELL AS STIMULATE CYTOKINE PRODUCTION AND ACTIVATE MACROPHAGES. | CORIXA CORPORATION | 2004-07-20 | — | — | US | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 60/4885SELP 996/4885TLR2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.